BH3 Mimetics in Relapsed and Refractory Adult Acute Lymphoblastic Leukemia: a Campus ALL Real-life Study

Overview

Journal Haematologica

Specialty Hematology

Date 2023 Oct 5

PMID 37794811

Authors

Francesco Malfona

Ilaria Tanasi

Matteo Piccini

Cristina Papayannidis

Vincenzo Federico

Valentina Mancini

Elisa Roncoroni

Elisabetta Todisco

Simona Bianchi

Giulia Ciotti

Patrizia Chiusolo

Massimo Gentile

Valentina Gianfelici

Fabio Giglio

Michele Malagola

Antonino Mule

Francesco Saraceni

Calogero Vetro

Francesco Zallio

Luca Vincenzo Cappelli

Giovanni Pizzolo

Robin Foa

Massimiliano Bonifacio

Sabina Chiaretti

Affiliations

Soon will be listed here.

Citing Articles

Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia.

Sergio I, Varricchio C, Squillante F, Cantale Aeo N, Campese A, Felli M Int J Mol Sci. 2024; 25(23).

PMID: 39684550 PMC: 11641392. DOI: 10.3390/ijms252312839.

References

Short N, Macaron W, Konopleva M, Ravandi F, Jain N, Issa G . Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022; 97(6):E201-E204. PMC: 11832082. DOI: 10.1002/ajh.26526. View

Wintering A, Ishiyama K, Tamaki S, Tamaki C, Fandel J, Ji L . CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2022; 7(2):251-255. PMC: 9840233. DOI: 10.1182/bloodadvances.2021006810. View

Pullarkat V, Lacayo N, Jabbour E, Rubnitz J, Bajel A, Laetsch T . Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021; 11(6):1440-1453. PMC: 9533326. DOI: 10.1158/2159-8290.CD-20-1465. View

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

Khaw S, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva R . Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016; 128(10):1382-95. PMC: 5016707. DOI: 10.1182/blood-2016-03-707414. View

Gokbuget N, Dombret H, Ribera J, Fielding A, Advani A, Bassan R . International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016; 101(12):1524-1533. PMC: 5479605. DOI: 10.3324/haematol.2016.144311. View

Wenge D, Wethmar K, Klar C, Kolve H, Sauer T, Angenendt L . Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia. Cancers (Basel). 2022; 14(3). PMC: 8833618. DOI: 10.3390/cancers14030565. View

Canaani J, Frisch A, Pollyea D, Schwartz M, Aumann S, Ganzel C . Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. Eur J Haematol. 2023; 111(3):365-372. DOI: 10.1111/ejh.14015. View

Benito J, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H . MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015; 13(12):2715-27. PMC: 4700051. DOI: 10.1016/j.celrep.2015.12.003. View

10.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

11.

Richard-Carpentier G, Jabbour E, Short N, Rausch C, Savoy J, Bose P . Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020; 20(4):212-218. DOI: 10.1016/j.clml.2019.09.608. View

12.

Leonard J, Rowley J, Eide C, Traer E, Hayes-Lattin B, Loriaux M . Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016; 8(354):354ra114. DOI: 10.1126/scitranslmed.aaf5309. View

13.

Frismantas V, Dobay M, Rinaldi A, Tchinda J, Dunn S, Kunz J . Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017; 129(11):e26-e37. PMC: 5356455. DOI: 10.1182/blood-2016-09-738070. View

14.

Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E . Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2020; 137(14):1879-1894. DOI: 10.1182/blood.2020007311. View